Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Intestinal Cell News 5.01 January 18, 2019 | |
 | |
| |
TOP STORYScientists found that mouse and human Lgr5+ intestinal stem cells (ISCs) showed high expression of the immune cell-associated circular RNA circPan3. Deletion of circPan3 in Lgr5+ ISCs impaired their self-renewal capacity and the regeneration of gut epithelium in a manner dependent on immune cells. [Nat Immunol] Abstract | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Arid1a Is Essential for Intestinal Stem Cells through Sox9 Regulation Sox9 overexpression permitted development of spheroids from Arid1a-deficient intestinal epithelial cells. In addition, deletion of Arid1a concomitant with Sox9 overexpression in Lgr5+ intestinal stem cells (ISCs) restored self-renewal in Arid1a-deleted Lgr5+ ISCs. [Proc Natl Acad Sci USA] Abstract N-terminal acetylation of cell cycle and apoptosis regulator 2 (CCAR2) diminished its interactions with histone deacetylase 3 and β-catenin, interfering with Wnt coactivator functions of CCAR2, including in cells harboring genetically encoded CCAR2 acetylation. [Cancer Res] Abstract Investigators showed that mono-ADP-ribosylated H3R117 of LoVo cells depressed demethylation of tumor suppressor TFPI2 promoter by suppressing TET1 expression and adjusting H3K9me3 enrichment of TFPI2 promoter to attenuate affinity of TET1, besides, since high H3K27me3 level was associated with hypermethylation, mono-ADP-ribosylated-H3R117-depended-H3K27me3 of TFPI2 promoter may contribute to hypermethylation of TFPI2. [Oncogene] Full Article Inhibition of Polyamine Biosynthesis Reverses Ca2+ Channel Remodeling in Colon Cancer Cells Consistently, difluoromethylornithine (DFMO) enhance Ca2+ store content and decreased store-operated Ca2+ entry in colorectal cancer (CRC) cells. Moreover, DFMO abolished selectively the transient receptor potential canonical type 1 channel-dependent component of store-operated channels characteristic of CRC cells and this effect was reversed by the polyamine putrescine. [Cancers] Full Article Researchers describe a real-time analysis of the cytotoxicity of putrescine and cadaverine on intestinal cell cultures. Both biogenic amines (BA) were cytotoxic at concentrations found in BA-rich foods, although the cytotoxicity threshold for cadaverine was twice that of putrescine. Their mode of cytotoxic action was similar, with both BA causing cell necrosis; they did not induce apoptosis. [Sci Rep] Full Article A Novel Tankyrase Inhibitor, MSC2504877, Enhances the Effects of Clinical CDK4/6 Inhibitors The authors showed that the clinical CDK4/6 inhibitor palbociclib, caused enhanced sensitivity to MSC2504877. This tankyrase inhibitor-CDK4/6 inhibitor combinatorial effect was not limited to palbociclib and MSC2504877 and was elicited with other CDK4/6 inhibitors and toolbox tankyrase inhibitors. [Sci Rep] Full Article Human Intestinal Enteroids as a Model System of Shigella Pathogenesis Scientists showed that Shigella flexneri invades polarized human intestinal enteroid (HIE) monolayers preferentially via the basolateral surface. After S. flexneri invaded HIE monolayers, S. flexneri replicated within HIE cells and formed actin tails. S. flexneri also increased the expression of HIE pro-inflammatory signals and the amino acid transporter SLC7A5. [Infect Immun] Abstract The biotinylated miR-222 specifically bound to the zipcode binding protein-1 (ZBP1) and phospholipase C-γ1 (PLC-γ1) mRNAs in intestinal epithelial cells. Ectopically expressed miR-222 precursor destabilized the ZBP1 and PLC-γ1 mRNAs and consequently lowered the levels of cellular ZBP1 and PLC-γ1 proteins. [Am J Physiol Cell Physiol] Abstract LncRNA-UCA1 Modulates Progression of Colon Cancer through Regulating the miR-28-5p/HOXB3 Axis Functional assays revealed that both urothelial carcinoma–associated 1 (UCA1) knockdown and miR-28-5p overexpression could inhibit colon cancer cell growth and migration. Further mechanistic studies indicated that UCA1 knockdown played tumor suppressive roles in SW480 and HT116 cells through binding with miR-28-5p. [J Cell Biochem] Abstract Subscribe to one of our other 19 science newsletters such as Pulmonary Cell News & ESC & iPSC News. | |
| |
| |
REVIEWSShortcuts to Intestinal Carcinogenesis by Genetic Engineering in Organoids Whereas carcinogenesis has been observed only at the organism level, the recent development of organoid culture technique has enabled long-term propagation of intestinal stem cells in a physiological setting, raising the possibility that organoids could serve as an alternative platform for modeling colon carcinogenesis. [Cancer Sci] Full Article Visit our reviews page to see a complete list of reviews in the intestinal cell research field. | |
| |
SCIENCE NEWSFive Prime Therapeutics Presents Data from Safety Lead-In to Phase III FIGHT Trial of Bemarituzumab Five Prime Therapeutics, Inc. announced that a poster entitled “Phase I Results from the Phase I/III FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Cancer” was presented. [Press release from Five Prime Therapeutics, Inc. discussing research presented at the ASCO Gastrointestinal (GI) Cancer Symposium, San Francisco] Press Release Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented MacroGenics, Inc. announced presentation of updated data from its Phase II clinical trial of margetuximab plus pembrolizumab for patients with advanced HER2+ gastric carcinoma in a poster session. [Press release from MacroGenics, Inc. discussing research presented at the ASCO Gastrointestinal (GI) Cancer Symposium, San Francisco] Press Release | |
| |
| |
INDUSTRY NEWSIronwood Pharmaceuticals, Inc. announced that the National Medical Products Administration approved the marketing application for LINZESS® for adults with irritable bowel syndrome with constipation (IBS-C) in China. Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019. [Ironwood Pharmaceuticals, Inc.] Press Release Pierre Fabre announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase III BEACON CRC trial evaluating the triplet combination of BRAFTOVI®, a BRAF inhibitor, MEKTOVI®, a MEK inhibitor and ERBITUX®, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC). [Pierre Fabre Group] Press Release ASLAN Pharmaceuticals announced an update on its global placebo-controlled, double-blind Phase II clinical study of varlitinib as a first-line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients, comparing varlitinib plus mFOLFOX6 to placebo plus mFOLFOX6. [ASLAN Pharmaceuticals] Press Release Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study Orion Biotechnology Canada Ltd. announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O in colorectal cancer. [Orion Biotechnology Canada Ltd.] Press Release | |
| |
POLICY NEWSCrash-Out Brexit Looms Larger for Scientists after Deal Rejected A historic defeat for U.K. Prime Minister Theresa May has raised the odds that the United Kingdom will crash out of the European Union in March, a prospect that scientists dread for its potential for disruption to research collaborations and the economy. [ScienceInsider] Editorial German Institutions and Wiley Reach Open-Access Publishing Deal Ater nearly three years of contract negotiations, a consortium of nearly 700 German libraries, research institutes, and universities called Project DEAL has forged an agreement with the scholarly publisher Wiley that moves the publishing industry towards more open access. [The Scientist] Editorial How UK Scientists Are Planning for a Chaotic No-Deal Brexit British scientists are ramping up preparations for a ‘no deal’ Brexit on 29 March — a situation that would instantly affect travel, data collection, clinical trials and crucial laboratory supplies. [Nature News] Editorial
| |
EVENTSNEW 2nd Annual Meeting of the American Society for Gene & Cell Therapy (ASGCT) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Assistant – Stem Cell Biology of the Intestine (Cancer Research UK Cambridge Institute) Postdoctoral Position – Colon Cancer (Vanderbilt University) Postdoctoral Fellow – Intetinal Stem Cell & Cancer (Francis Crick Institute) Postdoctoral Researcher – Vitamin D & IBD (University of Copenhagen) Postdoctoral Position – Colon Cancer (German Cancer Research Center) Postdoctoral Fellow – Intestinal Immune System (Washington University School of Medicine, St.Louis) Research Scientist – Intestinal Biology (Evotec AG) Associate Professor – Oncology (University of California, Davis) Postdoctoral Position – Paneth Cells (Erasmus MC Cancer Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Intestinal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
